Methoxyamine

DRUG6 trials

Sponsors

Case Comprehensive Cancer Center, National Cancer Institute (NCI)

Conditions

Adult Brain GlioblastomaAdult Nasal Type Extranodal NK/T-cell LymphomaAdvanced Malignant Solid NeoplasmAdvanced Peritoneal Malignant MesotheliomaAdvanced Pleural Malignant MesotheliomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaCutaneous B-cell Non-Hodgkin Lymphoma

Phase 1

Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

CompletedNCT00892385

Case Comprehensive Cancer CenterUnspecified Adult Solid Tumor, Protocol Specific

Start: 2007-08-16End: 2017-03-08Updated: 2019-02-22

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

CompletedNCT01658319

Case Comprehensive Cancer CenterAdult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma +31

Start: 2011-05-31End: 2015-05-31Updated: 2015-08-13

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer

CompletedNCT02535325

National Cancer Institute (NCI)Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIA Lung Adenocarcinoma AJCC v7, Stage IIIA Lung Large Cell Carcinoma AJCC v7 +10

Start: 2015-09-30End: 2022-06-14Updated: 2022-06-30

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Active, not recruitingNCT02535312

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma +4

Start: 2016-03-08End: 2026-10-15Updated: 2026-04-03

Phase 2

Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma

TerminatedNCT02395692

National Cancer Institute (NCI)Adult Brain Glioblastoma

Start: 2015-12-18End: 2017-02-16Updated: 2019-04-04

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

RecruitingNCT05198830

National Cancer Institute (NCI)Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma +1

Start: 2022-12-15End: 2027-06-30Target: 42Updated: 2026-04-03

Related Papers

Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT

Clinical Cancer Research2024-06-054 citations

Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.

Journal of Clinical Oncology2020-05-201 citations

Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial.

Journal of Clinical Oncology2020-05-20

Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors.

Journal of Clinical Oncology2015-05-203 citations